ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.…
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates
ADC Therapeutics (NYSE: ADCT) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 188 employees.
The shares were at 1.280 USD on 20 November 2026, down 68.2% over 52 weeks. Its 52-week range is 0.7800 USD to 4.980 USD: the price is 74.3% below the high and 64.1% above the low.
Its market capitalisation is 180.05M USD.
ADC Therapeutics reports return on equity of 76.7%, an operating margin of -92.9% and revenue up 32.2% year over year.
Its debt exceeds its cash by 252.70M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 3.333 USD is 160.4% above the current price. The next earnings report is expected on 10 March 2027.